Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
105
resultados
Última actualización
26/07/2026 [07:08:00]
Resumen de: US20260207687A1
0000 A composition of bacteriophages comprising at least one phage selected from TTS1, TTS2, TTS3, TTS4, TTS5, and TTS6, wherein the phages are optionally encapsulated; and a method for preventing or treating an infection caused by Salmonella Gallinarum by administering to a subject a therapeutically effective amount of the composition.
Resumen de: CN122427295A
本发明涉及生物技术、动物防疫领域，具体涉及一种α和ε型产气荚膜梭菌的融合蛋白、亚单位疫苗组合物及其应用。本发明通过将产气荚膜梭菌ε蛋白片段、产气荚膜梭菌α蛋白片段、鼠伤寒沙门氏菌鞭毛蛋白片段利用柔性连接肽顺序连接，构建得到了一种无毒力、安全性高、能够有效刺激机体产生抗体的融合蛋白，其氨基酸序列如SEQ ID NO:13所示。该融合蛋白经大量分泌表达后，蛋白含量不低于575μg/mL，蛋白纯度不低于87%。本发明进一步以融合蛋白为抗原，制备得到了一种能够同时预防产气荚膜梭菌α毒素和ε毒素引起的疾病的亚单位疫苗组合物，其制备方法简单、生产成本低，免疫效果好，具有高效的中和与攻毒保护能力，持久免疫应答能力，同时质量稳定、安全性高。
Resumen de: US20260200994A1
This application relates to compositions and methods used to treat animals with at least one microbial protein, such as a flagellin protein. In embodiments, application relates to compositions and methods to treat animals with a fusion protein comprising at least one adjuvant protein, such as a flagellin protein. In embodiments, the composition further includes at least one adjuvantic protein fused with at least one antigen protein, and the fusion protein is expressed in diatoms.
Resumen de: US20260201361A1
0000 The invention relates to guided nucleases, CRISPR/Cas systems, crRNAs, single gRNAs, vectors, methods and pharmaceutical compositions, for example for targeting sporulating bacteria, or for targeting C difficile, Salmonella, E coli or Streptococcus.
Resumen de: AU2026205168A1
Synthetic binding agents for reducing the fraction of targets that can permeate through mucus and/or freely divide, and methods of reducing mucosal permeation and/or free division of a target using these synthetic binding agents. un u n
Resumen de: CN122351451A
本发明提供了一种预防幽门螺杆菌感染的组合物及制备方法和应用。所述组合物包括外膜囊泡混合物和嗜黏蛋白阿克曼氏菌菌液；所述外膜囊泡混合物由沙门菌突变株QS0074的外膜囊泡和大肠杆菌E. coli Nissle 1917的外膜囊泡按照重量比2:1组成；所述外膜囊泡混合物和嗜黏蛋白阿克曼氏菌菌液的重量体积比为1mg:1mL。本发明所得组合物在攻毒试验中，显著优于对照组，具有高效的预防幽门螺杆菌感染的效果。同时，本发明的组合物各组分之间在诱导小鼠产生分泌性IgA水平和分泌性IgA水平以及诱导小鼠产生抵抗幽门螺杆菌感染能力方面，均产生了明显的协同作用，具有良好的应用前景。
Resumen de: WO2026148245A1
The present disclosure relates to microbials for use in E. coli, Salmonella, Enterococcus and/or Clostridium inhibition in animals and their environment. More particularly, the present disclosure relates to isolated Bacillus strains MDG-844 (NRRL No. B-68469), MDG-UF7 (NRRL No. B-68470), MDG-UC25 (NRRL No. B-68471), and MDG-I60 (NRRL No. B-68472), and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use.
Resumen de: US20260191946A1
This invention relates to the field of biomedicine and specifically to a porcine interferon-like recombinant protein and its applications. By constructing and screening a PoIFN-α DNA shuffling bacterial library, a highly active recombinant protein Porferon was obtained. Porferon exhibits potent anti-infective activity against a broad range of porcine pathogens, including viruses, bacteria, and parasites. Its biological activity is significantly superior to that of natural porcine interferon. As such, Porferon can be used in the development of therapeutics for the prevention or treatment of infectious diseases in pigs, offering a novel and effective solution for clinical applications in veterinary medicine.
Resumen de: US20260183346A1
0000 The composition and methods of treatment disclosed or contemplated herein include compositions and methods of treatment for liver-related diseases. The overall treatment strategy would involve the identification of a target protein or receptor within the liver that is responsible for ongoing liver injury. The strain of orally administered Salmonella Typhimurium that colonizes the liver would be engineered to secrete a particular protein or nanobody that would stop and/or reverse the progressive hepatic disease
Resumen de: WO2025042889A1
The present disclosure provides formulations, kits, and vaccines directed to immunization of animals against Salmonella. Methods of usng the formulations, kits, and vaccines for protection of avians against one or more species of Salmonella are also provided.
Resumen de: CN122297663A
本发明涉及生物蛋白应用技术领域，公开了鞭毛蛋白高变区H作为分子内佐剂在制备疫苗中的应用。鞭毛蛋白高变区H的氨基酸序列如SEQ ID NO.3所示，编码鞭毛蛋白高变区H的基因的核苷酸序列如SEQ ID NO.4所示。本发明还公开了含有编码鞭毛蛋白高变区H的基因的表达盒、重组载体、重组细胞或重组菌。本发明采用上述的鞭毛蛋白高变区H作为分子内佐剂在制备疫苗中的应用，本发明将鞭毛蛋白高变区H与抗原表位相连接得到融合蛋白，与现有技术相比，融合蛋白的可溶性和活性得到提高，同时本发明克服了现有大肠杆菌表达系统中包涵体的表达形式，后期不需要重新折叠组装，精简了疫苗制备工艺。
Resumen de: WO2024254147A1
The present disclosure relates, in part, to a polypeptide of formula (I), or a salt or solvate thereof, and a vaccine composition thereof further comprising at least one pharmaceutically acceptable excipient. The present disclosure further relates to isolated mRNA and/or isolated polynucleotides encoding the polypeptide of formula (I), vectors and/or LNPs comprising the same, and pharmaceutical compositions thereof. The present disclosure further relates to methods of treating, preventing, and/or ameliorating a bacterial infection, and/or generating immunity to infection by one or more pathogenic bacteria, in a subject in need thereof, the method comprising administering to the subject at least one composition of the present disclosure. In certain embodiments, the bacterial infection is a urinary tract infection, sepsis (e.g, neonatal sepsis), or pneumonia.
Resumen de: KR20260099243A
본 발명은 간접 ELISA에 보조 진단법으로 활용되거나 양돈장에서 돼지 부종병에 대한 감염 여부를 확인하기 위한 적정한 진단법으로 활용될 수 있는 Stx2e에 대한 단클론 항체 및 다중클론 항체를 활용한 sandwich ELISA에 의한 혈중 및 분변 내 Stx2e 항원량 측정 방법에 관한 것이다.
Resumen de: CN122278469A
本发明公开一种无金属毒害的高敏快速荧光探针、制备方法及其在食品致病菌检测中的应用，属于食品检测技术领域。该探针由有机荧光分子石墨烯复合主体、有机无机杂化掺杂剂及特异性识别分子构成；掺杂剂为羧基化纤维素与二氧化硅纳米颗粒，其与复合主体质量比为1:6~10；特异性识别分子采用致病菌适配体，经喷雾涂覆接枝于探针表面。该探针依靠适配体与目标致病菌的特异性结合触发荧光响应，可在5 min内完成检测，灵敏度≥90%，特异性≥98%；探针不含金属成分，无毒害与环境风险，适用于食品现场快速检测及畜禽活体检测；同时制备成本降低90%，单样本检测成本降低40%，具备良好应用前景。
Resumen de: WO2024025312A1
The present invention relates to a recombinant expression vector for secretion of IFN-β proteins and an attenuated Salmonella strain transformed by means of same, and provides: a recombinant expression vector comprising flgM genes, IFN-β genes, and flhDC genes; an attenuated Salmonella strain transformed by means of same; and a pharmaceutical composition for cancer treatment comprising the attenuated Salmonella strain as an active ingredient.
Resumen de: EP4279503A1
0001 Provided is a method that enables the presence and/or amount of bacteria of Enterobacteriaceae in a food/drink sample, an environmental sample, or a biological sample to be detected easily and efficiently in a short amount of time. Said method includes a step for simultaneously detecting, on the basis of an antigen-antibody reaction, the presence and/or amount of bacteria of Enterobacteriaceae of at least two different genera in a sample.
Resumen de: CN120992924A
The invention belongs to the technical field of Ultrap1 enzyme quantitative detection, and particularly relates to an Ultrap1 enzyme double-antibody sandwich ELISA (enzyme-linked immuno sorbent assay) kit and application. Comprising an elisa plate coated with an anti-Ultrap1 enzyme mouse monoclonal antibody, an anti-Ultrap1 enzyme rabbit polyclonal antibody, an HRP-labeled goat anti-rabbit antibody, a diluent, a cleaning solution, a confining solution, a developing solution and a stop solution. According to the present invention, the complex of the Ulp1 enzyme and the SUMO tag protein is adopted as the immunogen to simultaneously immunize mice and New Zealand rabbits so as to prepare different species of the good affinity Ulp1 enzyme antibodies, and then the optimal reaction condition is further screened to develop the stable double-antibody sandwich ELISA detection kit with characteristics of high specificity and strong sensitivity, the defects in the prior art can be effectively overcome.
Resumen de: CN122214226A
本发明公开了一种htrA基因敲除的减毒沙门氏菌重组工程菌株及其应用，对减毒沙门氏菌VNP20009进行基因组遗传改造，将基因组中的htrA基因敲除，获得ΔhtrA‑VNP菌株。通过回补性表达带有/不带有信号肽的HtrA蛋白，首次证实信号肽对于HtrA蛋白的功能发挥至关重要。无信号肽的htrA基因回补菌株与ΔhtrA‑VNP菌株生物学表型无显著差异。本发明所述的表达带有信号肽的HtrA蛋白的ΔhtrA‑VNP菌株，HtrA蛋白通过调控细菌胞外多糖水平，一方面影响菌株的免疫原性与抗癌效果，另一方面影响菌株对抗巨噬细胞的杀伤效果，进而影响细菌在体内的分布特性。本发明基于htrA基因活性作用模式，建立了瘤内时空特异性启动表达带有信号肽的HtrA蛋白的ΔhtrA‑VNP菌株，实现更高效、安全与精准的活体微生物抗肿瘤治疗。
Resumen de: CN122182751A
本发明公开了一种细菌复合疫苗与顺铂的协同抗肿瘤组合及其应用，属于肿瘤药物制备技术领域。所述抗肿瘤组合包括以下成份：细菌复合疫苗和顺铂。本发明通过细菌复合疫苗和顺铂的协同配合，在对肿瘤模型的试验小鼠进行治疗时发现，相较于单一的细菌复合疫苗治疗组和单一的顺铂治疗组，二者的协同用药对肿瘤细胞增殖的抑制作用显著上升，具有良好的抗肿瘤效果。
Resumen de: US20260158079A1
Provided herein are compositions comprising substantially non-viable Gram-negative bacterial organisms that have a substantial reduction in endotoxin activity and/or pyrogenicity and methods for treating a cancer using the same. Also provided are methods for treating cancer provided herein, comprising administering to a mammal diagnosed with cancer, substantially non-viable Gram-negative bacteria having a substantial reduction in endotoxin activity and/or pyrogenicity, in an amount sufficient to inhibit growth or metastasis of the cancer. An additional method is provided comprising administering viable or non-viable Gram-negative bacterial organisms that have a genetic defect that results in a substantial loss of lipopolysaccharide within the outer membrane of the bacteria. Further provided are methods for reducing endotoxin activity and/or pyrogenicity in Gram-negative bacteria comprising treatment with polymyxin and glutaraldehyde.
Resumen de: AU2024374864A1
Cyclic dinucleotides, which are a type of signaling substance for cancer treatment, are secondary messengers of intracellular events initiated by GPCR activation and act as a stimulator of interferon genes (STING), and thus can have a significant effect on tumor suppression. Meanwhile, when cancer occurs in a subject, angiogenesis and cell growth proceed at a very high rate in the body, and thus an oxygen-deficient environment is created due to incomplete angiogenesis in cancer tissues, which may be very suitable for the proliferation of anaerobic bacteria such as Salmonella sp. strains or E. coli. Therefore, the present invention relates to a DNA construct into which is introduced a gene for an enzyme that synthesizes a signaling substance for cancer treatment, e.g., a cyclic dinucleotide, or to a strain transformed with a vector comprising the DNA construct. The DNA construct or the strain transformed with a vector comprising the DNA construct, according to the present invention, targets cancer in a subject and then secretes C-di-AMP or C-di-GMP synthase in the surrounding environment of the cancer, and thus can very effectively prevent or treat cancer and, at the same time, can diagnose cancer in real time.
Resumen de: KR20260084896A
본 발명은 콜레라균 또는 장티푸스균에 특이적인 단일클론 항체 및 이를 이용한 콜레라와 장티푸스 동시 신속진단키트에 관한 것으로, 보다 상세하게는 서열번호 2, 서열번호 4, 서열번호 6 또는 서열번호 8의 아미노산 서열로 표시되는 중쇄 가변영역을 포함하는 콜레라균(Vibrio cholerae)에 특이적으로 결합하는 단일클론 항체 및 서열번호 10 또는 서열번호 12의 아미노산 서열로 표시되는 중쇄 가변영역을 포함하는 살모넬라 티피(Salmonella typhi)에 특이적으로 결합하는 단일클론 항체를 이용한 콜레라와 장티푸스 동시 신속진단키트에 관한 것이다.
Resumen de: AU2026203814A1
The present disclosure relates generally to compositions, dosage forms, and methods for preventing and treating infections. The compositions include intact and substantially non- viable Gram-negative bacterial cells which have been treated to reduce lipopolysaccharide (LPS)-associated endotoxin activity, which surprisingly have increased activity to trigger immune cell production of cytokines. ay a y
Resumen de: MX2026005882A
Disclosed herein are methods and systems for rapid detection of microorganisms such as Listeria spp. in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Listeria-specific bacteriophage, allows detection of a specific microorganism, such as Listeria spp. and an indicator signal may be amplified to optimize assay sensitivity.
Nº publicación: CN122104609A 29/05/2026
Solicitante:
WUHU INST OF TECHNOLOGY
\u829C\u6E56\u804C\u4E1A\u6280\u672F\u5B66\u9662
Resumen de: CN122104609A
The invention discloses a long-tailed bacteriophage and application thereof. The preservation name of the bacteriophage is WHSATYSB-2501, the preservation number of the bacteriophage is CCTCC No: M 2026038, and the bacteriophage is preserved in the China Center for Type Culture Collection on January 8, 2026. The bacteriophage can be used for preparing a bactericide or a disinfectant, and can also be used for inhibiting or cracking salmonella typhimurium. The long-tailed bacteriophage WHSATYSB-2501 obtained through separation can efficiently kill salmonella typhimurium in sewage, the titer can reach 6.8 * 10 < 11 > PFU/mL when the optimal infection complex number is 0.01, and the splitting and inhibiting effects on salmonella typhimurium are remarkably higher than those of existing bacteriophages. The application scene and the application range of the bacteriophage in salmonella prevention and control are remarkably widened, and an efficient and stable novel technical means is provided for biological prevention and control of salmonella.
BOPI
Sede Electrónica
